Trevi Therapeutics Stock (NASDAQ:TRVI)

Forecast Ownership Financials Chart Transcripts

Previous Close

$14.41

52W Range

$5.38 - $16.12

50D Avg

$12.25

200D Avg

$10.54

Market Cap

$2.00B

Avg Vol (3M)

$1.46M

Beta

1.00

Div Yield

TRVI Company Profile

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

May 07, 2019

Website

TRVI Performance

TRVI Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	$-49.33M	$-51.52M	$-33.92M
Net Income	$-42.76M	$-47.91M	$-29.07M
EBITDA	$-49.33M	$-47.79M	$-28.58M
Basic EPS	$-0.32	$-0.47	$-0.29
Diluted EPS	$-0.32	$-0.47	$-0.29

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q4 25Mar 17, 26 | 12:00 AM

Q3 25Nov 13, 25 | 4:30 PM

Q2 25Aug 08, 25 | 4:30 PM

Peer Comparison

Ticker	Company
TERN	Terns Pharmaceuticals, Inc.
NVAX	Novavax, Inc.
UPB	Upstream Bio, Inc.
ZYME	Zymeworks Inc.
ORIC	ORIC Pharmaceuticals, Inc.
ARDX	Ardelyx, Inc.
PGEN	Precigen, Inc.
WVE	Wave Life Sciences Ltd.
ZBIO	Zenas BioPharma, Inc.
TRML	Tourmaline Bio, Inc.